The publication of this article was funded by GSK.*
Antimicrobial Resistance: A Spotlight on Urinary Tract Infections – Is there an issue?
In recent years, there has been a notable increase in antimicrobial resistance and multi-drug resistance among community-acquired uropathogens, predominantly Escherichia coli and Klebsiella pneumoniae, causing urinary tract infections (UTI). The availability of effective oral treatments limited by antimicrobial resistance is of growing concern.
This article reviews sessions that took place between 20th–22nd October 2022 as part of IDWeek2022 in Washington, D.C., USA.
Antimicrobial resistance in urinary tract infections: Is there an issue?
Highlighting coverage of an immersive expert-led Learning Lounge sponsored by GSK, as well as presentations and posters delivered during the IDWeek2022 scientific program, speakers delivered contemporary surveillance data of antimicrobial resistance in community-acquired UTIs, identifying the importance of antimicrobial stewardship, as well as the emergence of prospective antimicrobial treatments.
Read the full article for further details and expert insights shared at the conference.
Compliance number: NX-GBL-GPT-EML-220002: February 2023
*The views and opinions expressed in this article are exclusively those of the speakers and do not necessarily reflect those of GSK. GSK was provided with the opportunity to review this publication for the sole purpose of ensuring its data is accurately stated herein. Not all medicines and/or indications presented in this report may be approved for use in all countries. The speakers listed are GSK paid healthcare providers or GSK employees. The content is intended to support disease state education and is considered nonpromotional. The Learning Lounge was neither endorsed nor sponsored by IDWeek.